Pharma giant Pfizer has agreed to pay $486 million to close the books on a decade-long class-action securities lawsuit related to two of the company’s pain relievers, Celebrex and Bextra. [More]
The Wall Street Journal Health Blog has some “eye-popping” news — a doctor has been caught fabricating 21 drug studies, some of which were favorable to drugs that have since been pulled from the market — Merck’s Vioxx and Pfizer’s Bextra.
A new ad for Celebrex, a prescription painkiller related to Vioxx, has come under fire for implying that Celebrex is as safe as non-prescription painkillers such as ibuprofen (Advil, Motrin) and naproxen (Aleve.) A consumer group has written a letter to the FDA requesting that they ban the ad, claiming that it contains “false or misleading statements.”
“The overall purpose of the ad is to make it appear, contrary to scientific evidence, that the cardiovascular dangers of Celebrex are not greater than those of any of the other Nsaid painkillers,” the letter said, referring to nonsteroidal anti-inflammatory drugs. “Further, it asserts that certain gastrointestinal problems are, if anything, less frequent with Celebrex than with two popular over-the-counter (OTC) painkillers.”
The ad, which is two-and-a-half minutes long (Pfizer was the only sponsor of the program on which it aired), can be viewed at Celebrex.com. The ad marks Celebrex’s return to advertising after a two year hiatus following Vioxx’s withdrawal from the market due to dangerous cardiovascular side-effects.